Related Articles
Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs
miR‑135b‑5p enhances the sensitivity of HER‑2 positive breast cancer to trastuzumab via binding to cyclin D2
Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer
miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8
Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells